HBK Sorce Advisory’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $314K | Sell |
6,222
-584
| -9% | -$31.6K | 0.01% | 486 |
|
|
2025
Q4 | $410K | Sell |
6,806
-1,374
| -17% | -$64.1K | 0.01% | 407 |
|
|
2025
Q3 | $358K | Buy |
8,180
+939
| +13% | +$36.7K | 0.01% | 430 |
|
|
2025
Q2 | $278K | Buy |
+7,241
| New | +$277K | 0.01% | 479 |
|
|
2022
Q3 | – | Sell |
-4,421
| Closed | -$241K | – | 620 |
|
|
2022
Q2 | $241K | Sell |
4,421
-14
| -0.3% | -$773 | 0.02% | 385 |
|
|
2022
Q1 | $241K | Buy |
4,435
+633
| +17% | +$34.4K | 0.01% | 453 |
|
|
2021
Q4 | $210K | Buy |
+3,802
| New | +$198K | 0.01% | 549 |
|
|
2021
Q3 | – | Sell |
-5,029
| Closed | -$250K | – | 595 |
|
|
2021
Q2 | $250K | Sell |
5,029
-1,045
| -17% | -$50.2K | 0.01% | 489 |
|
|
2021
Q1 | $271K | Buy |
6,074
+526
| +9% | +$23.9K | 0.02% | 423 |
|
|
2020
Q4 | $255K | Sell |
5,548
-1,814
| -25% | -$83.3K | 0.02% | 418 |
|
|
2020
Q3 | $346K | Sell |
7,362
-377
| -5% | -$18.9K | 0.02% | 328 |
|
|
2020
Q2 | $395K | Buy |
7,739
+275
| +4% | +$14.1K | 0.03% | 288 |
|
|
2020
Q1 | $353K | Sell |
7,464
-512
| -6% | -$27.3K | 0.03% | 270 |
|
|
2019
Q4 | $469K | Buy |
7,976
+690
| +9% | +$38.4K | 0.04% | 276 |
|
|
2019
Q3 | $389K | Sell |
7,286
-90
| -1% | -$4.63K | 0.04% | 284 |
|
|
2019
Q2 | $369K | Buy |
7,376
+400
| +6% | +$20.1K | 0.04% | 292 |
|
|
2019
Q1 | $364K | Buy |
6,976
+109
| +2% | +$5.45K | 0.04% | 303 |
|
|
2018
Q4 | $328K | Sell |
6,867
-3,249
| -32% | -$160K | 0.04% | 284 |
|
|
2018
Q3 | $461K | Buy |
10,116
+2,362
| +30% | +$120K | 0.05% | 232 |
|
|
2018
Q2 | $391K | Sell |
7,754
-2,076
| -21% | -$105K | 0.05% | 265 |
|
|
2018
Q1 | $480K | Sell |
9,830
-23
| -0.2% | -$1.07K | 0.06% | 219 |
|
|
2017
Q4 | $437K | Sell |
9,853
-6,902
| -41% | -$319K | 0.05% | 243 |
|
|
2017
Q3 | $850K | Buy |
16,755
+4,719
| +39% | +$239K | 0.13% | 114 |
|
|
2017
Q2 | $649K | Buy |
+12,036
| New | +$642K | 0.1% | 143 |
|
|
2017
Q1 | – | Sell |
-10,484
| Closed | -$532K | – | 354 |
|
|
2016
Q4 | $505K | Buy |
10,484
+872
| +9% | +$43.1K | 0.09% | 158 |
|
|
2016
Q3 | $518K | Buy |
9,612
+210
| +2% | +$11.5K | 0.1% | 145 |
|
|
2016
Q2 | $509K | Buy |
9,402
+349
| +4% | +$18.4K | 0.11% | 142 |
|
|
2016
Q1 | $459K | Buy |
+9,053
| New | +$451K | 0.11% | 135 |
|
Other funds holding GSK
JEST
HBK Sorce Advisory's GSK Position: Q1 2026 in Review
HBK Sorce Advisory reduced its GSK (GSK) stake by 8.6% in Q1 2026, selling an estimated $31.6K and leaving 6,222 shares worth $314K. The position accounts for 0.01% of the portfolio, ranked #486.
HBK Sorce Advisory first reported a position in GSK in Q1 2016 and has held it in 28 quarters since. The position peaked at $850K in Q3 2017. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- HBK Sorce Advisory held 6,222 shares of GSK worth $314K as of Q1 2026.
- HBK Sorce Advisory sold 584 GSK shares in Q1 2026, an estimated $31.6K.
- GSK made up 0.01% of HBK Sorce Advisory's portfolio in Q1 2026, its #486 holding.
- HBK Sorce Advisory first reported a position in GSK in Q1 2016 and has held it in 28 quarters since.
- HBK Sorce Advisory's GSK position peaked at $850K in Q3 2017.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on HBK Sorce Advisory's 13F filing for Q1 2026, filed 11 May 2026.